suma/hypoxia

This study is a multi-centre randomized controlled, open label, phase II trial for patients with de-novo GBM. Eligible patients will be randomized between arm A and arm B: Arm A (standard): Radiotherapy and chemotherapy according to standard protocol for newly diagnosed GBM. This consists of 30

This trial has been designed as an open label, single center combination phase I trial. The primary objective is to determine the maximum tolerated dose (MTD) for chloroquine (CQ) in combination with concurrent radiotherapy with daily temozolomide in patients with a newly diagnosed GBM. Eligible

The administration of oral metformin during radiotherapy is thought to decrease the hypoxic fraction of tumour cells, improving radiosensitivity and promoting apoptosis, resulting in better outcome. This hypothesis will be evaluated in a trial with randomized design. All patients willing to

This study proposes the examine the effects of Acute Intermittent Hypoxia (AIH) in combination with upper extremity training, over the course of a month, to evaluate changes in upper extremity function, dexterity, and ability to complete activities of daily living. The use of acute intermittent

Subjects undergoing elective ERCP and EUS will receive standard monitoring and sedation. In addition, capnography which measures carbon dioxide levels and can graphically assess respiratory activity will be used. Subjects will be randomized to either a capnography blinded or titration arm. In the

The study will investigate digoxin to inhibit the hypoxic response in congenital erythrocytosis due to germ line mutations that result in up-regulated hypoxia sensing. These forms of congenital erythrocytosis, characterized by augmented levels of hypoxia inducible factor (HIF)-1 and/or HIF-2, are

Aim: To analyse tiny cancer cell fragments called extracellular vesicles isolated from blood samples for their ability to identify patients with tumours that are relatively oxygen-starved and expected to be resistant to ionising radiation and many chemotherapy drugs. Participants: 16 patients with

The dogma over the past 3 decades, particularly in the field of sleep medicine, has been that intermittent hypoxia (IH) is a detrimental stimulus that leads to a number of co‐morbidities including autonomic (e.g. increased sympathetic nervous system activity), cardiovascular (e.g. hypertension,

This study has 6 primary objectives/hypotheses: 1. Replicate findings of earlier study in which no effects of altitude were observed on post sleep neurobehavioral performance, sleep quantity or quality. 2. Determine if sleep at 6000 feet has effects similar to sleep at 8000 feet. 3. Identify if

Objective of the study The aim of this study is to: - evaluate a hypoxia imaging agent, HX4, in patients with solitary tumors (i.e., locally advanced head and neck cancer) - gain information on bio-distribution of [F-18]HX4 - compare the PET images of [F-18] FMISO to [F-18]HX4 for resolution, signal